Pre‐emptive versus non pre‐emptive kidney transplantation for end‐stage kidney disease by Olarte Parra, Camila et al.
                          Olarte Parra, C., Van de Bruaene, C., Weynants, L., Nagler, E. V.,
McAleenan, A., Elbers, R. G., ... Goetghebeur, E. (2018). Preemptive versus
non preemptive kidney transplantation for endstage kidney disease.
Cochrane Database of Systematic Reviews, (12), [CD013073].
https://doi.org/10.1002/14651858.CD013073
Publisher's PDF, also known as Version of record
Link to published version (if available):
10.1002/14651858.CD013073
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via the Cochrane
Library at https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013073/full . Please refer to any
applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Cochrane Database of Systematic Reviews
Pre-emptive versus non pre-emptive kidney transplantation
for end-stage kidney disease (Protocol)
Olarte Parra C, Van de Bruaene C, Weynants L, Nagler EV, McAleenan A, Elbers RG, Higgins JPT,
Goetghebeur E
Olarte Parra C, Van de Bruaene C, Weynants L, Nagler EV, McAleenan A, Elbers RG, Higgins JPT, Goetghebeur E.
Pre-emptive versus non pre-emptive kidney transplantation for end-stage kidney disease.
Cochrane Database of Systematic Reviews 2018, Issue 12. Art. No.: CD013073.
DOI: 10.1002/14651858.CD013073.
www.cochranelibrary.com
Pre-emptive versus non pre-emptive kidney transplantation for end-stage kidney disease (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iPre-emptive versus non pre-emptive kidney transplantation for end-stage kidney disease (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
Pre-emptive versus non pre-emptive kidney transplantation
for end-stage kidney disease
Camila Olarte Parra1, Cedric Van de Bruaene2, Laurens Weynants3, Evi V Nagler4, Alexandra McAleenan5, Roy G Elbers5, Julian P
T Higgins5 , Els Goetghebeur1
1Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium. 2Department of Internal
Medicine, Ghent University Hospital, Ghent, Belgium. 3Department of Urology, Ghent University Hospital, Ghent, Belgium. 4Renal
Division, Sector Metabolic and Cardiovascular Conditions, Ghent University Hospital, Ghent, Belgium. 5Population Health Sciences,
Bristol Medical School, University of Bristol, Bristol, UK
Contact address: Camila Olarte Parra, Department of Applied Mathematics, Computer Science and Statistics, Ghent University,
Campus Sterre, S9, Krijgslaan 281, Ghent, East Flanders, 9000, Belgium. Camila.OlarteParra@UGent.be.
Editorial group: Cochrane Kidney and Transplant Group.
Publication status and date: New, published in Issue 12, 2018.
Citation: Olarte Parra C, Van de Bruaene C, Weynants L, Nagler EV, McAleenan A, Elbers RG, Higgins JPT, Goetghebeur E. Pre-
emptive versus non pre-emptive kidney transplantation for end-stage kidney disease. Cochrane Database of Systematic Reviews 2018,
Issue 12. Art. No.: CD013073. DOI: 10.1002/14651858.CD013073.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
This review aims to look at the benefits and harms of pre-emptive kidney transplantation compared with kidney transplantation after
dialysis for patients with ESKD.
B A C K G R O U N D
Description of the condition
People with end-stage kidney disease (ESKD) require renal re-
placement therapy (RRT), either as dialysis or kidney transplanta-
tion. Most people prefer kidney transplantation over dialysis, be-
cause it is seen as generally prolonging their life and substantially
improving its quality.
It is estimated that each year 80,000 kidney transplants are per-
formed around the world (Tong 2017). Despite the possibility of
living donor kidney transplantation, organ demand far exceeds
organ availability worldwide, and the number of patients listed
for kidney transplantation continues to rise (ANZDATA 2016;
Branger 2015; ERA-EDTA 2017; OPTN/SRTR 2012). In 2016,
close to 100,000 people were waiting for a donor kidney in the
USA alone.
Description of the intervention
Most transplant physicians consider pre-emptive transplantation
- before dialysis initiation - the best option for the individual pa-
tient. First, it avoids the reduction in quality of life associated with
dialysis (Howell 2012; Tong 2017). Second, several registry-based
studies have suggested that indeed those receiving a donor kidney
pre-emptively have better patient and graft survival than those be-
ing transplanted after having started dialysis (Abramowicz 2016).
However, such observational data carry an important risk of bias.
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In addition, the optimal timing of pre-emptive transplantation re-
mains controversial and increased pre-emptive listingmay increase
the waiting time for those patients already established on dialysis.
The rates of pre-emptive transplantation reported in these registry-
based studies vary depending on the country and on the popula-
tion. In studies of adults, the reported rates ranged between 2.3%
in a US-based study (including both deceased and living donors)
(Pradel 2008) to 22% in a study of transplantation in Australia
and New Zealand (all from living donors) (Milton 2008). In pae-
diatric populations, the frequency of pre-emptive transplantation
ranged between 14% for the Eurotransplant area (8% for cadaveric
donors and 39% for living donors; The Eurotransplant area covers
Austria, Belgium, Germany, Luxembourg, The Netherlands and
Slovenia) (Cransberg 2006) to 28% in the USA (18% for cadav-
eric donors and 35% for living donors) (Butani 2011).
How the intervention might work
Chronic dialysis patients generally consider their quality of life
to be substantially better after transplantation. Many are able to
resume their professional activities, family and social lives im-
prove, and energy levels increase (Howell 2012; Malone 2017;
Tong 2017). In addition, dialysis requires creation of a vascular
access, and often repeated interventions to maintain its function
(Abramowicz 2016; Pradel 2008).
The average survival after kidney transplantation is better than on
dialysis. More than half the deaths among adults treated with dial-
ysis are caused by cardiovascular disease; dialysis is often implicated
as the main contributor (Foley 2005; Goodman 2000; Kutner
2012). Hence, avoiding dialysis altogether may explain why pre-
emptive kidney transplant recipients live longer and possibly have
better graft outcome too. For children, dialysis is associated with
poor growth and impaired neurocognitive development (Butani
2011; Cransberg 2006).
Yet, one could think of mechanisms causing a decrease rather than
improvement in outcome. Patientswhohave experienced the hard-
ships of dialysis may value transplantation more and adhere more
closely to anti-rejection therapy (Cransberg 2000; Dobbels 2005;
Pradel 2008). In addition, the earlier the transplant, the longer
the exposure to immunosuppressive medications, with subsequent
increased risk of infection and cancer (Butani 2011; Vajdic 2006;
Webster 2007).
Why it is important to do this review
The ERA-EDTA Descartes working group and European Renal
Best Practice (ERBP) conducted a systematic review in 2016 to as-
sess whether pre-emptive kidney transplantation versus transplan-
tation after having started dialysis improves outcomes for recipi-
ents of kidneys from living donors (Abramowicz 2016). Thework-
ing group recommended that programmes for pre-emptive trans-
plantation with living donor kidneys should be encouraged. Al-
though they classified this recommendation as strong, they consid-
ered that the certainty of the evidence to be very low (Abramowicz
2016).
Their review process identified only cohort studies, all registry-
based and frequently relying on transplant registries. With trans-
plant registries, the follow-up starts at transplantation and the pe-
riod under dialysis is not accounted for. Consequently, there is
differential follow-up between the group being transplanted pre-
emptively, where start of treatment matches the start of follow-
up, and the group being transplanted after having started dial-
ysis, where follow-up starts after treatment onset. This results
in lead-time bias (Hernan 2016). Moreover, people who receive
a kidney pre-emptively tend to be healthier, less anaemic, and
better fed; they have better residual kidney function, and fewer
cardiovascular co-morbidities, resulting in selection bias, possi-
bly explaining the seemingly improved results after transplanta-
tion (Abramowicz 2016; Cransberg 2000; Goldfarb-Rumyantzev
2005; Kutner 2012). Therefore, the current review aims to iden-
tify and assess the methods used to address the potential benefit
of pre-emptive kidney transplantation and the quality of evidence
provided for decision making to highlight limitations in the ap-
proaches currently used.
The ultimate aim of our review is to determine whether the indi-
vidual patient with ESKD set to undergo transplantation benefits
from being transplanted before dialysis is initiated. It will expand
the scope of the review conducted by the ERA-EDTA Descartes
working group and ERBP in order to include both living and de-
ceased donors, as both scenarios are encountered in daily practice.
Even if the individual benefits from pre-emptive kidney transplan-
tation, we acknowledge there may be barriers for implementation
of this strategy within the societal context of organ shortage; fur-
ther research will be needed to assess the effect that such a change
may have for the waiting list and how to optimise current alloca-
tion algorithms to safeguard equity. This is beyond the scope of
this review.
O B J E C T I V E S
This review aims to look at the benefits and harms of pre-emptive
kidney transplantation compared with kidney transplantation af-
ter dialysis for patients with ESKD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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Eligible for the review are all randomised controlled trials (RCTs),
quasi-RCTs (RCTs in which allocation to treatment was obtained
by alternation, use of alternate medical records, date of birth or
other predictable methods) and cohort studies that compared pre-
emptive kidney transplantation with transplantation after having
started dialysis in people eligible for transplantation.
Althoughwe are aiming to includeRCTs,we donot expect them to
exist. The choice between pre-emptive transplantation and trans-
plantation after having started dialysis is mainly driven by the local
allocation algorithm, in case of deceased donation, which consid-
ers factors such as time on the waiting list. For living donation,
scheduling of the procedure depends on the time required to assess
suitability of potential living donors. A recipient with a suitable
donor already identified would probably prefer to undergo trans-
plantation instead of giving consent for a trial that could delay
the procedure. This makes it unlikely that RCTs will have been
performed. In addition, the systematic review by the ERA-EDTA
Descartes working group and ERBP only identified observational
studies.
We will only include studies published after 1990, as we consider
earlier studies to be outdated in terms of current practice in surgical
techniques and immunosuppressive therapy (Abramowicz 2016).
There will be no restrictions regarding the language of the study.
Types of participants
Inclusion criteria
All people of any age (both children and adults) eligible for kidney
transplantation, regardless of underlying kidney disease, of type of
dialysis received, if any, or whether they have history of previous
kidney transplantation. We anticipate a wide variation of patients
considered suitable for transplant depending on local centre policy.
Exclusion criteria




Pre-emptive kidney transplantation: transplantation before having
started chronic haemodialysis (HD) or peritoneal dialysis (PD),
as defined by the authors. No restriction will be made regarding
the baseline GFR at transplantation.
Comparator
Transplantation after having started chronic HD or PD. There
will be no restrictions on dialysis modality (home HD, in-centre
HD, night-time, daily) or duration of dialysis (dialysis vintage).
Even though both living and deceased donors will be included, the
comparison will be performed separately for each donor type. No
restriction will be made for donors with brain death or circulatory
death.
Types of outcome measures
The domain and outcomes selected follow the core outcome set for
kidney transplantation as specified by the Standardised Outcomes
in Nephrology for transplantation (SONG-Tx) (SONG 2017).
Primary outcomes
Death (all causes) for the follow-up available in the study and point
estimates at one, five and 10 years after transplant.
Secondary outcomes
Table 1. Secondary outcomes
Domain Dimension Dimension Type Time point
Graft health Graft survival Graft loss (death, requir-
ing RRT)





Dichotomous 1, 5 and 10 years after transplant
Kidney function eGFR Continuous 1, 5 and 10 years after transplant
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(Continued)
CrCl Continuous 1, 5 and 10 years after transplant
Life participation Quality of life Any scale reported by au-
thors (e.g. SF-36, EQ-
5D)
Continuous 1, 5 and 10 years after transplant
Cardiovascular disease Cardiovascular disease
incidence
Incidence Dichotomous 1, 5 and 10 years after transplant
Cancer Cancer incidence Incidence Dichotomous 1, 5 and 10 years after transplant
Infection Infection incidence Incidence Dichotomous 1, 5 and 10 years after transplant
eGFR - estimated glomerular filtration rate; CrCl - creatinine clearance; RRT - renal replacement therapy
Table 1 shows the secondary outcomes. There are likely to be some
studies in which graft failure is defined as return to dialysis or
re-transplantation and others that consider it to be a composite
outcome that includes both these events and death. For those
studies that do not consider death as graft failure, graft failure and
death are competing risks.Whenever possible both death-censored
graft survival and graft failure including death will be provided.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Kidney and Transplant Specialised
Register through contact with the Information Specialist using
search terms relevant to this review. The Specialised Register con-
tains studies identified from the following sources:
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of kidney-related journals and the
proceedings of major kidney conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected kidney and
transplant journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of Cochrane Kidney and Transplant. Details of these
strategies, as well as a list of handsearched journals, conference
proceedings and current awareness alerts, are available in the Spe-
cialised Register section of information about Cochrane Kidney
and Transplant.
For non-randomised studies, MEDLINE (OVID) and EMBASE
(OVID) will be searched.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of review articles, relevant studies and
clinical practice guidelines.
2. Letters seeking information about unpublished or
incomplete trials to investigators known to be involved in
previous studies.
Data collection and analysis
Selection of studies
The search strategy described will be used to obtain titles and
abstracts of studies that may be relevant to the review. The titles
and abstracts will be screened independently by two authors, who
will discard studies that are not applicable; however studies and
reviews that might include relevant data or information on trials
will be retained initially. Two authors will independently assess
retrieved abstracts and, if necessary the full text, of these studies
to determine which studies satisfy the inclusion criteria.
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Data extraction and management
Data extraction will be carried out independently by two authors
using standardized data extraction forms. Studies reported in non-
English language journals will be translated before assessment.
Where more than one publication of one study exists, reports will
be grouped together and the publication with the most complete
data will be used in the analyses. Where relevant outcomes are
only published in earlier versions these data will be used. Any
discrepancy between published versions will be highlighted.
Assessment of risk of bias in included studies
Randomised studies
The following items will be independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study?
◦ Participants and personnel (performance bias)
◦ Outcome assessors (detection bias)
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
Non-randomised studies
Non-randomised studies will be assessed using the Risk of Bias
in Non-Randomised Studies of Interventions (ROBINS-I) tool
(Sterne 2016a). The tool assesses risk of bias in 7 domains (con-
founding, selection into the study, classification of interventions,
deviations from intended interventions, missing data, measure-
ment of outcomes, and selection of the reported result) according
to signalling questions that encompass issues before, during and
after the intervention (Sterne 2016a) (see Appendix 3).
To apply the tool, a target hypothetical trial is specified against
which the non-randomised study is compared. An ideal hypothet-
ical RCT for this review is a clinical trial that randomises patients
eligible for kidney transplantation to either pre-emptive transplan-
tation or to a period of dialysis (haemodialysis or peritoneal dial-
ysis at the discretion of the treating clinician) followed by trans-
plantation; and then follows patients from randomisation. Peri-
odic data regarding kidney function, graft failure and death would
be recorded. Data analysis would be conducted according to in-
tention-to-treat principles.
Two of the domains of ROBINS-I require pre-specification of
important confounders and co-interventions. The confounders
and co-interventions thatwe consider to be both potentially related
to the intervention and are prognostic for mortality are listed in
Table 2 (Foley 2005; KDIGO 2013; Kutner 2012).





• Cause of kidney disease




• Level of HLA sensitisation
Immunosuppression therapy
HLA - human leukocyte antigen
To apply the ROBINS-I tool, two authors will independently an-
swer the signalling questions to grade each of the seven domains
and give an overall risk of bias for each study (Sterne 2016a) (see
Appendix 3). Any disagreements will be discussed to reach a con-
sensus and a third author will be consulted if necessary. The bias
assessment for each study, including their specific target trial, risk
of bias for each separate domain and the overall risk of bias, will
be presented in the final report of the review.
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Measures of treatment effect
For dichotomous outcomes (e.g. death and graft failure after one,
five and 10 years of transplantation) results will be expressed as risk
ratios (RR)with 95%confidence intervals (CI).Where continuous
scales of measurement are used to assess the effects of treatment
(e.g. kidney function and quality of life after one, five and 10 years
of transplantation), the mean difference (MD) will be used, or the
standardised mean difference (SMD) if different scales have been
used.
For time-to-event outcomes (e.g. time to death and/or graft failure
for the available follow-up in the study) results will be expressed
as a hazard ratio (HR) with 95% CI. In case that HR and/or
CI are not reported, the methods developed by Parmar 1998 and
Williamson 1998 will be used to extract the relevant information
for estimating them whenever possible.
It is worth noting that these methods were developed for RCTs,
where confounding is not a major concern given that the treat-
ment is assigned randomly. As this is not the case for observational
studies, adjusting for confounding factors becomes crucial for the
causal effect estimate. When the study provides both crude and
adjusted treatment effect estimates, both will be included, as they
will shed light on any confounder bias.
Differences in the causal effect estimate can arise when assessing
different populations, as the joint distribution of their covariates
may vary. Moreover, differences can be seen when adjusting for
different subsets of confounders and/or using different adjusting
methods. Therefore the marginal effect measured is expected to
differ if the covariates adjusted for differ or different approaches
of dealing with confounding are used, for instance when dealing
with time-varying confounding. If and when possible, we would
aim to generate directly standardized risks referring to a common
underlying confounder distribution at baseline, following the list
of the minimum set of confounders previously presented (Table
2). In any case, the adjusted estimate will be preferred over the
crude estimate and we will have to rely on the choice of covariates
and methods for adjustment chosen by the authors and aim to be
explicit what the adjusted effect is exactly measuring.
WhenHRchange over time, it is inappropriate to report an average
HR, as the estimate would depend on the time of follow-up (
Hernan 2010). Therefore, if the proportional hazards assumption
is violated, the follow-up will be divided into epochs to make an
average estimate of the HR within epochs.
Unit of analysis issues
Non-standard designs are not expected for this review.
Dealing with missing data
Any further information required from the original author will be
requested by written correspondence (e.g. emailing corresponding
author) and any relevant information obtained in this manner
will be included in the review. Evaluation of important numerical
data such as screened, randomised patients as well as intention-
to-treat, as-treated and per-protocol population will be carefully
performed. Attrition rates, for example drop-outs, losses to follow-
up and withdrawals will be investigated. Issues of missing data
and imputation methods (for example, last-observation-carried-
forward) will be critically appraised (Higgins 2011).
Assessment of heterogeneity
We will first assess the heterogeneity by visual inspection of the
forest plot. We will quantify statistical heterogeneity using the I
2 statistic, which describes the percentage of total variation across
studies that is due to heterogeneity rather than sampling error
(Higgins 2003).
The importance of the observed value of I2 depends on the mag-
nitude and direction of treatment effects and the strength of evi-
dence for heterogeneity (e.g. P-value from the Chi2 test, or a con-
fidence interval for I2) (Higgins 2011).
Assessment of reporting biases
If possible, funnel plots will be used to assess for the potential
existence of small study bias (Higgins 2011).
Data synthesis
We will report our findings separately by donor source (living
versus cadaveric). If we consider that the studies are similar in
terms of participants, interventions, comparators and outcomes
then a meta-analysis will be performed. Data will be combined
across studies using the random-effects model considering that
the intervention effect is not the same for all studies but rather
follows a distribution across the studies. However, the fixed-effect
model will also be used to ensure robustness of results to themodel
chosen and susceptibility to outliers.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses will be performed to explore possible sources of
heterogeneity (e.g. RCT versus non-RCT, adult versus children).
Crude versus adjusted estimates and the nature of covariates ad-
justed for will also be compared, given that they could vary from
study to study. Heterogeneity in treatment effects could be related
to previous type of dialysis (for those in the transplantation after
dialysis arm) and duration of dialysis (for both groups, as there
could be differences in definitions of pre-emptive kidney trans-
plantation between studies, allowing for short-term dialysis versus
no time in dialysis at all). Differences may also arise from differ-
ent starting points of follow-up (date of transplantation in both
groups versus onset of dialysis in the dialysis followed by transplan-
tation arm), the duration of the follow-up (particularly if there are
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time-varying hazards), inclusion criteria for transplant recipients,
quality of the study and adjusting for different confounding fac-
tors. Additional sources of heterogeneity include differences in the
population in terms of covariates (e.g. age and underlying kidney
disease) and organ availability in the setting where the study was
carried out.
Sensitivity analysis
We will perform sensitivity analyses to explore the robustness of
the findings to the following factors:
• Repeating the analysis excluding unpublished studies
• Repeating the analysis taking account of risk of bias,
excluding RCTs with high risk of bias or non-randomised studies
with serious or critical risk of bias
• Repeating the analysis excluding any very long or large
studies to establish how much they dominate the results
• Repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), and country
• Repeating the analysis excluding studies that differ in the
choice of covariates on which they adjusted for, taking into
account the most frequent covariates that studies include as
confounders as the minimum required.
’Summary of findings’ tables
We will present the main results of the review in ’Summary of
findings’ tables. These tables present key information concerning
the quality of the evidence, the magnitude of the effects of the
interventions examined, and the sum of the available data for the
main outcomes (Schünemann 2011a). The ’Summary of findings’
tables also include an overall grading of the evidence related to
each of the main outcomes using the GRADE (Grades of Recom-
mendation, Assessment, Development and Evaluation) approach
(GRADE 2008; GRADE 2011). The GRADE approach defines
the quality of a body of evidence as the extent to which one can
be confident that an estimate of effect or association is close to the
true quantity of specific interest. The quality of a body of evidence
involves consideration of within-trial risk of bias (methodological
quality), directness of evidence, heterogeneity, precision of effect
estimates and risk of publication bias (Schünemann 2011b).
A ’Summary of findings’ table will be presented for each of the out-
comes assessed (death (all causes), graft survival, death-censored
graft survival, kidney function and quality of life), separating by
type of donor (deceased versus living donor).
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A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
CENTRAL 1. MeSH descriptor: [Kidney Transplantation] this term only
2. kidney transplant*:ti,ab,kw (Word variations have been searched)
3. {or #1-#2}
4. preemptive:ti,ab,kw (Word variations have been searched)
5. pre-emptive:ti,ab,kw (Word variations have been searched)
6. {or #4-#5}
7. {and #3, #6}
MEDLINE 1. exp Kidney Transplantation/
2. (pre-emptive or preemptive).tw.
3. “prior to dialysis”.tw.
4. (prior adj3 dialysis).tw.
5. (before adj4 dialysis).tw.
6. “transplant$ before dialysis”.tw.
7. (post adj start adj2 dialysis).tw.
8. or/2-7
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(Continued)
9. and/1,8
EMBASE 1. exp kidney transplantation/
2. (pre-emptive or preemptive).tw.
3. “prior to dialysis”.tw.
4. (prior adj3 dialysis).tw.
5. (before adj4 dialysis).tw.
6. “transplant$ before dialysis”.tw.
7. (post adj start adj2 dialysis).tw.
8. or/2-7
9. and/1,8
Appendix 2. Risk of bias assessment tool for RCT
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimisation (minimisation may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
quate concealment of allocations prior to assignment
Low risk of bias: Randomisation method described that would not
allow investigator/participant to know or influence intervention
group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
procedure
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(Continued)
Unclear: Randomisation stated but no information on method
used is available
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
data, the proportion ofmissing outcomes comparedwith observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardised difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
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(Continued)
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. sub-scales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
High risk of bias: Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
imbalance; has been claimed to have been fraudulent; had some
other problem
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
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Appendix 3. Risk of bias assessment tool for non-randomised studies
Overall risk of bias assessment using ROBINS-I tool (Sterne 2016b)
Bias assessment Criteria
Low risk of bias The study is comparable to a well-performed randomised trial
Moderate risk of bias The study provides sound evidence for a non-randomised study but cannot be considered comparable to a
well-performed randomised trial
Serious risk of bias The study has some important problems
Critical risk of bias The study is too problematic to provide any useful evidence and should not be included in any synthesis
No information No information on which to base a judgement about risk of bias
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